NextTrip Inc

Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NextTrip, Inc. engages in the provision of travel technology solutions. It connects people to new places and discoveries by utilizing digital media engagement, seasoned planning expertise, and unique inventory to curate custom vacations across the globe. The company was founded on December 23, 1985 and is headquartered in Sunrise, FL.

SUNRISE, FL / ACCESSWIRE / April 2, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip", "we," "our," or the "Company"), a travel technology company, has engaged international investor relations specialists MZ Group (MZ) to lead a comprehensive strategic investor relations and financial communications program across all key markets. MZ Group will work closely with NextTrip management to develop and implement a comprehensive capital markets strategy designed to increase the Company's visibility throughout the investment community.

NextTrip Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback the hedge funds employing these talents and can benefit from their vast resources and knowledge in that way. We analyze quarterly 13F filings of nearly 817 hedge funds and, by looking at the smart money sentiment that surrounds a stock, we can determine whether it has the potential to beat the market over the long-term. Therefore, let's take a closer look at what smart money thinks about Neurotrope, Inc. (NASDAQ:NTRP).

Is Neurotrope, Inc. (NTRP) A Good Stock To Buy According To Hedge Funds?

NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP) ("Neurotrope" or the "Company") announced today that its Board of Directors has approved the conditional distribution and set the shareholder of record and distribution dates in connection with the previously...

Neurotrope, Inc. Approves Spin-Off of Neurotrope Bioscience, Inc. and Sets Record and Distribution Dates

NEW YORK and MANALAPAN TOWNSHIP, N.J., Sept. 30, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company focused on innovative therapeutics for men's health conditions ("Metuchen"), today announced that they...

Neurotrope Shareholders to Own 49 Percent of Petros Under Revised Merger Agreement with Metuchen

NEW YORK and MANALAPAN TOWNSHIP, N.J., May 18, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company ("Metuchen"), focused on identifying, developing, acquiring, and commercializing innovative therapeutics for...

Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company

Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP) gap-opened sharply higher on above 50 times average volume following a corporate update from the company.

Neurotrope Rips 150% Higher On Improved Alzheimer's Data, NIH Funding

It may be unusual to see a stock rise close to 100% without a corporate buyout, but in biotech and emerging pharmaceutical companies gains of that size can occur simply with a drug study update from even a small number of patients.

Some Great News for Potential Alzheimer’s Treatment

Shares of Neurotrope Inc. NTRP, -77.95% plummeted 79% on heavy volume Monday, to below the $1 mark for the first time in six years, after the biopharmaceutical company said its Alzheimer's disease (AD) treatment failed to meet the primary endpoint of a phase 2 trial.

Neurotrope's stock plummets on heavy volume after disappointing trial of Alzheimer's treatment

Shares of thinly-traded nano-cap biotech Neurotrope Inc (NASDAQ: NTRP) were plummeting Monday following an adverse clinical trial readout.

Why Neurotrope Is Plunging On Heavy Volume

Neurotrope has been struggling lately, but the selling pressure may be coming to an end soon.

Neurotrope Sees Hammer Chart Pattern: Time to Buy?

Investors need to pay close attention to Neurotrope (NTRP) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Neurotrope (NTRP) Stock?

Anavex Life Sciences

The biotechnology sector is generally considered the most volatile and riskiest sector within all of healthcare.

Two Very Speculative Biotechs With Promising Alzheimer’s Treatment Hopefuls

Neurotrope, Inc. may be a winner by default in the battle against Alzheimer’s disease after shares of Biogen Inc. suffered handily with the announcement that it and partner Eisei were halting late-stage studies of aducanumab.

Is Neurotrope the Default Alzheimer’s Winner After Biogen’s Implosion?

News for NextTrip Inc Stock (NTRP)